logo
 
iNCOVACC, the world's first intranasal vaccine by Bharat Biotech has received both primary series and Heterologous booster approval, the Hyderedab-based company said on Monday.

In a release regarding the same, Bharat Biotech said, iNCOVACC (BBV 154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above, in India, for heterologous booster doses.

The intranasal vaccine had earlier received approval under Restricted Use in Emergency Situation for ages 18 and above for the primary 2-dose schedule. Phase III trials were conducted for safety, immunogenicity in~3100 subjects, at 14 trial sites across India.

Meanwhile, the heterologous booster dose studies were conducted for safety and



immunogenicity in ~875 subjects, with BBV154 intranasal vaccine administered post 2 doses of the two commonly administered COVID-19 vaccines. The trials were conducted at 9 trial sites across India.

Speaking on the recent development, Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech, said, “This is a great achievement for us and the global scientific community to enable nasal administration of COVID vaccines. Despite the lack of demand for COVID vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases. 

“We thank the Ministry of Health, CDSCO, Dept of Biotechnology, Govt of India, Technology Development Board, and Washington University, St. Louis, for their support and guidance, " he added. 
No Comments For This Post, Be first to write a Comment.
Leave a Comment
Name:
Email:
Comment:
Enter the code shown:


Can't read the image? click here to refresh

Todays Epaper

English Weekly

neerus indian ethnic wear
Latest Urdu News

Do you think CM KCR will manage to unite all opposition parties for the 2024 Lok Sabha polls?

Yes
No
Can't Say